Skip to main content

PROCESOS CATALITICOS PARA LA CONVERSION DE CO2 EN PRODUCTOS DE INTERES INDUSTRIAL

CTQ2017-84131-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DE CASTILLA-LA MANCHA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Polylactide perspectives in biomedicine: from novel synthesis to the application performance

  • Moya López, Carmen
  • González Fuentes, Joaquín
  • Bravo, Iván
  • Chapron, David
  • Bourson, Patrice
  • Alonso Moreno, Carlos
  • Hermida Merino, Daniel
The incessant developments in the pharmaceutical and biomedical fields, particularly, customised solutions for specific diseases with targeted therapeutic treatments, require the design of multicomponent materials with multifunctional capabilities. Biodegradable polymers offer a variety of tailored physicochemical properties minimising health adverse side effects at a low price and weight, which are ideal to design matrices for hybrid materials. PLAs emerge as an ideal candidate to develop novel materials as are endowed withcombined ambivalent performance parameters. The state-of-the-art of use of PLA-based materials aimed at pharmaceutical and biomedical applications is reviewed, with an emphasis on the correlation between the synthesis and the processing conditions that define the nanostructure generated, with the final performance studies typically conducted with either therapeutic agents by in vitro and/or in vivo experiments or biomedical devices., Ministerio de Ciencia e Innovación | Ref. PID2020-117788RB-I00, Ministerio de Ciencia e Innovación | Ref. CTQ2017-84131-R, Ministerio de Ciencia e Innovación | Ref. RED2018-102387-T
Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Multifunctional PLA/gelatin bionanocomposites for tailored drug delivery systems

  • Moya López, Carmen
  • Juan, Alberto
  • Donizeti, Murillo
  • Valcarcel, Jesus
  • Vázquez, José A.
  • Solano, Eduardo
  • Chapron, David
  • Bourson, Patrice
  • Bravo, Ivan
  • Alonso Moreno, Carlos
  • Clemente Casares, Pilar
  • Gracia Fernández, Carlos
  • Longo, Alessandro
  • Salloum-Abou-Jaoude, Georges
  • Ocaña, Alberto
  • Martínez Piñeiro, Manuel
  • Hermida Merino, Carolina
  • Hermida Merino, Daniel
A series of bionanocomposites composed of shark gelatin hydrogels and PLA nanoparticles featuring different nanostructures were designed to generate multifunctional drug delivery systems with tailored release rates required for personalized treatment approaches. The global conception of the systems was considered from the desired customization of the drug release while featuring the viscoelastic properties needed for their ease of storage and posterior local administration as well as their biocompatibility and cell growth capability for the successful administration at the biomolecular level. The hydrogel matrix offers the support to develop a direct thermal method to convert the typical kinetic trapped nanostructures afforded by the formulation method whilst avoiding the detrimental nanoparticle agglomeration that diminishes their therapeutic effect. The nanoparticles generated were successfully formulated with two different antitumoral compounds (doxorubicin and dasatinib) possessing different structures to prove the loading versatility of the drug delivery system. The bionanocomposites were characterized by several techniques (SEM, DLS, RAMAN, DSC, SAXS/WAXS and rheology) as well as their reversible sol–gel transition upon thermal treatment that occurs during the drug delivery system preparation and the thermal annealing step. In addition, the local applicability of the drug delivery system was assessed by the so-called “syringe test” to validate both the storage capability and its flow properties at simulated physiological conditions. Finally, the drug release profiles of the doxorubicin from both the PLA nanoparticles or the bionanocomposites were analyzed and correlated to the nanostructure of the drug delivery system., Ministerio de Ciencia e Innovación y Agencia Estatal de la Investigación | Ref. PID2020- 117788RB-I00, Ministerio de Ciencia e Innovación y Agencia Estatal de la Investigación | Ref. RED2018-102387-T, Ministerio de Ciencia e Innovación y Agencia Estatal de la Investigación | Ref. CTQ2017-84131-R
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The Carbon Dioxide-Rumen Fermentation Processes-strategy, a proposal to sustain environmentally friendly dairy farms

  • Alonso-Moreno, Carlos
  • Garde, José Julián
  • Zafrilla, Jorge E.
  • Canales-Vázquez, Jesús
  • Gueddari, Abdessamad
  • García-Yuste, Santiago
A novel Carbon Dioxide Utilization (CDU) approach from a relatively minor biogenic carbon dioxide emission source, Rumen Fermentation Processes (RFP), is presented. The CO-RFP strategy explores the potential treatment of the liquid manure storage located at the bottom of the dairy barns with CO-enriched air coming from cattle exhalation and belching to produce an important fertilizer such as NHHCO (ABC, ammonium bicarbonate). The unusual CDU strategy, analyzed exclusively from a chemical point of view, could yield over 31.6 Million of tones, Mt, of ABC in aqueous solution using c. 18.0 Mt of CO and capturing c. 6.9 Mt of NH ammonia. This process would consume less energy than the traditional synthetic method (ABC fertilizer process) and would not produce any by-products or chemical compounds which may enter into conflict with the dairy sector. The quantity of ABC obtained by this strategy would be equivalent to four times the world production per year. Taking into consideration only the most relevant dairy countries, the estimate of the CO negative emission achieved suggests a capture of around 1.8 Gt of CO equivalents and 82.8 Mt of NH from now to 2030. With the aim of providing a realistic outlook on the CO-RFP strategy, the proposal is discussed considering a number of possible scenarios: the CO-RFP strategy (1) in a typical livestock dairy farm, (2) in the most relevant dairy countries and (3) as a N-fertilizer supplier., The authors gratefully acknowledge financial support from the Ministerio de Economía y Competividad (MINECO) of Spain (Grant Nos. Consolider-Ingenio 2010 ORFEO CSD 2007-00006, CTQ2014-52899-R, CTQ2017-84131-R, and Research Project ECO2016-78939-R). This work was also supported by Campus Científico y Tecnológico de la Energía y el Medioambiente: CYTEMA-UCLM., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Screening and preliminary biochemical and biological studies of [RuCl(p-cymene)(N, N-bis(diphenylphosphino)-isopropylamine)][BF4] in Breast Cancer Models

  • Corrales Sánchez, Verónica
  • Nieto-Jiménez, Cristina
  • Castro-Osma, José Antonio
  • De Andrés, Fernando
  • Pacheco-Liñán, Pedro J.
  • Bravo, Iván
  • Rodríguez Fariñas, Nuria
  • Niza, E.
  • Domínguez-Jurado, Elena
  • Lara-Sánchez, Agustín
  • Ríos, Ángel
  • Gómez-Juárez, Mónica
  • Montero, Juan Carlos
  • Pandiella, Atanasio
  • Shafir, Alexandr
  • Alonso-Moreno, Carlos
  • Ocaña, Alberto
Breast cancer is the second leading cause of cancer death worldwide. Despite progress in drug discovery, identification of the correct population is the limiting factor to develop new compounds in the clinical setting. Therefore, the aim of this study is to evaluate the effects of a new metallodrug, [RuCl(p-cymene)(N,N-bis(diphenylphosphino)-isopropylamine)][BF4] (pnpRu-14), as a lead pnp-Ru compound by screening and preliminary biochemical and biological studies in different breast cancer subtypes. The results show that complex pnpRu-14 is much more effective in promoting in vitro cytotoxic effects on HER2+ and RH+/HER2- breast cancer than the reference metallodrugs cisplatin, carboplatin, or RAPTA-C. It is important to highlight that pnpRu-14 shows an impressive cytotoxicity against BT474 cells. Caspase-dependent apoptosis is the mechanism of action for these compounds. In addition, treatment of SKBR3, BT474, T47D, and MCF7 cancer cells with pnpRu-14 caused an accumulation of cells in the G0/G1 phase cells. The human serum albumin, DNA, and H1 histones binding properties of the lead compound are reported. Pharmacokinetic and biodistribution studies show a quick absorption of pnpRu-14 in serum with no significant accumulation in any of the tested organs. This work provides evidence to support the preclinical and clinical development of pnpRu-14 in breast cancer. Copyright © 2019 American Chemical Society., The authors gratefully acknowledge financial support from the Ministerio de Economı́a y Competitividad (MINECO), Spain (grant nos. CTQ2017-84131-R, CTQ2016-81797-REDC) 350 Programa Redes Consolider CTQ2016-78793-P, CTQ2017-86936-P, the Instituto de Salud Carlos III (PI16/01121), ACEPAIN, Diputación de Albacete, CIBERONC, and CRIS Cancer Foundation (to A.O.) and JJCC Castilla-La Mancha (grant no. SBPLY/17/180501/000262), as well as AGAUR (Gen. Catalunya, 2017 SGR 1051). ED thanks AECC for financial support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy

  • Juan, Alberto
  • Cimas, Francisco J.
  • Bravo, Iván
  • Pandiella, Atanasio
  • Ocaña, Alberto
  • Alonso-Moreno, Carlos
© 2020 by the authors., Nanoparticles (NPs) are promising drug delivery systems (DDS) for identifying and treating cancer. Active targeting NPs can be generated by conjugation with ligands that bind overexpressed or mutant cell surface receptors on target cells that are poorly or not even expressed on normal cells. Receptor-mediated endocytosis of the NPs occurs and the drug is released inside the cell or in the surrounding tissue due to the bystander effect. Antibodies are the most frequently used ligands to actively target tumor cells. In this context, antibody-based therapies have been extensively used in HER2+ breast cancer. However, some patients inherently display resistance and in advanced stages, almost all eventually progress. Functionalized NPs through conjugation with antibodies appear to be a promising strategy to optimize targeted therapies due to properties related to biocompatibility, suitable delivery control and efficiency of functionalization. This review is focused on the different strategies to conjugate antibodies into polymeric NPs. Recent antibody conjugation approaches applied to the improvement of breast cancer therapy are highlighted in this review., We gratefully acknowledge financial support from Ministerio de Ciencia e Innovación, Spain (Grant Nos. CTQ2017-84131-R and CTQ2016-81797-REDC Programa Redes Consolider) (to C. Alonso-Moreno), and Instituto de Salud Carlos III (PI19/00808), CIBERONC and CRIS Cancer Foundation (to A. Ocaña)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment

  • Juan, Alberto
  • Cimas, Francisco J.
  • Bravo, Iván
  • Pandiella, Atanasio
  • Ocaña, Alberto
  • Alonso, Carlos
© 2020 by the authors, Breast cancer is the most common invasive tumor in women and the second leading cause of cancer-related death. Nanomedicine raises high expectations for millions of patients as it can provide better, more efficient, and affordable healthcare, and it has the potential to develop novel therapeutics for the treatment of solid tumors. In this regard, targeted therapies can be encapsulated into nanocarriers, and these nanovehicles are guided to the tumors through conjugation with antibodies—the so-called antibody-conjugated nanoparticles (ACNPs). ACNPs can preserve the chemical structure of drugs, deliver them in a controlled manner, and reduce toxicity. As certain breast cancer subtypes and indications have limited therapeutic options, this field provides hope for the future treatment of patients with difficult to treat breast cancers. In this review, we discuss the application of ACNPs for the treatment of this disease. Given the fact that ACNPs have shown clinical activity in this clinical setting, special emphasis on the role of the nanovehicles and their translation to the clinic is placed on the revision., This research was funded by Ministerio de Ciencia e Innovación, Spain, grant number CTQ2017-84131-R and CTQ2016-81797-REDC Programa Redes Consolider, and Instituto de Salud Carlos III grant number PI16/01121.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Tuning the Cytotoxicity of Bis-Phosphino-Amines Ruthenium(II) Para-Cymene Complexes for Clinical Development in Breast Cancer

  • Domínguez-Jurado, Elena
  • Cimas, Francisco J.
  • Castro-Osma, José Antonio
  • Juan, Alberto
  • Lara-Sánchez, Agustín
  • Rodríguez-Diéguez, Antonio
  • Shafir, Alexandr
  • Ocaña, Alberto
  • Alonso-Moreno, Carlos
Despite some limitations such as long-term side effects or the potential presence of intrinsic or acquired resistance, platinum compounds are key therapeutic components for the treatment of several solid tumors. To overcome these limitations, maintaining the same efficacy, organometallic ruthenium(II) compounds have been proposed as a viable alternative to platinum agents as they have a more favorable toxicity profile and represent an ideal template for both, high-throughput and rational drug design. To support the preclinical development of bis-phoshino-amine ruthenium compounds in the treatment of breast cancer, we carried out chemical modifications in the structure of these derivatives with the aim of designing less toxic and more efficient therapeutic agents. We report new bis-phoshino-amine ligands and the synthesis of their ruthenium counterparts. The novel ligands and compounds were fully characterized, water stability analyzed, and their in vitro cytotoxicity against a panel of tumor cell lines representative of different breast cancer subtypes was evaluated. The mechanism of action of the lead compound of the series was explored. In vivo toxicity was also assessed. The results obtained in this article might pave the way for the clinical development of these compounds in breast cancer therapy., We gratefully acknowledge the financial support from the Ministerio de Ciencia e Innovación y Agencia Estatal de la Investigación, Spain (Grant Nos. PID2020-117788RB-I00, PID2020-113661GB-I00, CTQ2017-84131-R and RED2018-102387-T Programa Redes Consolider), and Instituto de Salud Carlos III grant number PI16/01121. Alberto Ocaña’s lab is supported by the Instituto de Salud Carlos III (ISCIII, PI19/00808); CRIS Cancer Foundation, ACEPAIN, and Diputación de Albacete., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Multifunctional PLA/Gelatin Bionanocomposites for Tailored Drug Delivery Systems

  • Moya-López, Carmen
  • Juan, Alberto
  • Donizeti, Murillo
  • Valcárcel Barros, Jesús
  • Vázquez, José Antonio
  • Solano, Eduardo
  • Chapron, David
  • Bourson, Patrice
  • Bravo, Iván
  • Alonso-Moreno, Carlos
  • Clemente-Casares, Pilar
  • Gracia-Fernández, Carlos
  • Longo, Alessandro
  • Salloum-Abou-Jaoude, Georges
  • Ocaña, Alberto
  • Piñeiro, Manuel M.
  • Hermida-Merino, Carolina
  • Hermida-Merino, Daniel
21 pages, 10 figures, 2 tables.-- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, A series of bionanocomposites composed of shark gelatin hydrogels and PLA nanoparticles featuring different nanostructures were designed to generate multifunctional drug delivery systems with tailored release rates required for personalized treatment approaches. The global conception of the systems was considered from the desired customization of the drug release while featuring the viscoelastic properties needed for their ease of storage and posterior local administration as well as their biocompatibility and cell growth capability for the successful administration at the biomolecular level. The hydrogel matrix offers the support to develop a direct thermal method to convert the typical kinetic trapped nanostructures afforded by the formulation method whilst avoiding the detrimental nanoparticle agglomeration that diminishes their therapeutic effect. The nanoparticles generated were successfully formulated with two different antitumoral compounds (doxorubicin and dasatinib) possessing different structures to prove the loading versatility of the drug delivery system. The bionanocomposites were characterized by several techniques (SEM, DLS, RAMAN, DSC, SAXS/WAXS and rheology) as well as their reversible sol–gel transition upon thermal treatment that occurs during the drug delivery system preparation and the thermal annealing step. In addition, the local applicability of the drug delivery system was assessed by the so-called “syringe test” to validate both the storage capability and its flow properties at simulated physiological conditions. Finally, the drug release profiles of the doxorubicin from both the PLA nanoparticles or the bionanocomposites were analyzed and correlated to the nanostructure of the drug delivery system, We gratefully acknowledge the financial support from the Ministerio de Ciencia e Innovación y Agencia Estatal de la Investigación (10.13039/501100011033), Spain (Grant Nos. PID2020- 117788RB-I00, CTQ2017-84131-R and RED2018-102387-T Programa Redes Consolider), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Carbon dioxide fixation into cyclic carbonates at room temperature catalyzed by heteroscorpionate aluminum complexes

  • Cruz-Martínez, Felipe de la
  • Castro-Osma, José A.
  • Lara-Sánchez, Agustín
Novel mono- and bimetallic scorpionate aluminum compounds have been designed and characterized by spectroscopic methods. These organometallics complexes, in combination with tetrabutylammonium bromide as cocatalyst, displayed good catalytic activity for the cycloaddition of styrene oxide and CO under ambient conditions. Among the compounds tested, monometallic complex 3 featuring diethylamino groups showed the highest catalytic activity. This catalytic system catalyzed the formation of cyclic carbonate products from their corresponding epoxides at room temperature and 1 bar of CO pressure in the absence of a solvent in good yields and excellent selectivities.